Oral Oncology
Volume 38, Issue 4 , Pages 337-342 , June 2002

A comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositis

  • Jean-Louis Lefebvre

      Affiliations

    • C.R.L.C. Oscar Lambret, 1 rue Frédéric Combemale, B.P. 307 59020- Lille Cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-3-20-29-55-31; fax: +33-3-20-29-59-61
    • On behalf of the Study Group on Mucositis.
    • ,
  • Christian Domenge

      Affiliations

    • Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 - Villejuif Cedex, France
    • On behalf of the Study Group on Mucositis.

Received 26 February 2001 ,Revised 21 March 2001 ,Accepted 23 May 2001.

References 

  1. Mooney MA, Thomas I, Sirois D. Oral candidiasis. Int J Dermatol. 1995;34:759–765
  2. Epstein JB, Polsky B. Oropharyngeal candidiasis (a review of its clinical spectrum and current therapies). Clin Ther. 1998;20:40–57
  3. Peterson DE. Oral candidiasis. Clin Geriatr Med. 1992;8:513–527
  4. Garber GE. Treatment of oral Candida mucositis infections. Drugs. 1994;47:734–740
  5. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients (treatment issues). Clin Infect Dis. 1998;26:259–274
  6. Koletar SL, Russel JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidasis in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 1990;34:2267–2268
  7. Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE, Perfect JR. Oropharyngeal candidiasis in patients with HIV (suggested guidelines for therapy). AIDS Res Hum Retrovir. 1999;15:1619–1623
  8. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy. 1999;19:76–87
  9. Koks CHW, Meenhorst PL, Hillebrand MJX, Bult A, Beijnen JH. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob. Agents Chemother. 1996;40:1935–1937
  10. Laufen H, Yeates RA, Zimmermann T, de los Reyes C. Pharmacokinetic optimization of the treatment of oral candidiasis with fluconazole (studies with a suspension). Drugs Exp Clin Res. 1995;21:23–28
  11. Force RW, Nahata MC. Salivary concentrations of ketoconazole and fluconazole (implications for drug efficacy in oropharyngeal and esophageal candidiasis). Ann Pharmacother. 1995;29:10–15
  12. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Suppl 3):S318–S326
  13. De Wit S, Goossens H, Weerts D, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidasis in AIDS. Lancet. 1989;I:746–748
  14. Hay RJ. Overview of studies with fluconazole in oropharyngeal candidiasis. Rev Infect Dis. 1990;12(Suppl 3):S334–S337
  15. Hernandez-Sampelayo T. Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Eur J Clin Microbiol Infect Dis. 1994;13:340–344
  16. Meunier F, Aoun M, Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host (a randomized double-blind study of fluconazole vs. ketoconazole). Rev Infect Dis. 1990;12(suppl 3):S364–S368
  17. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidasis in HIV-infected patients (a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches). J Acquir Immun Defic Syndr. 1993;6:1311–1316
  18. Vandercam B, Gibbs D, Valtonen M, Jager H, Armignacco O. Fluconazole orally dispersible tablets for the treatment of patients with oropharyngeal candidiasis. J Intern Med Res. 1998;26:209–218
  19. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA, et al.  Oropharyngeal candidiasis in immunocompromised children (a randomized multicenter study of orally administered fluconazole suspension versus nystatin). J Pediatr. 1995;127:322–328
  20. Taillandier J, Esnault Y, Alemanni M. A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidiosis. Age Ageing. 2000;29:117–123
  21. Laine L, Rabeneck L. Prospective study of fluconazole suspension for the treatment of oesophageal candidasis in patients with AIDS. Aliment Pharmacol Ther. 1995;9:553–556
  22. Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidasis unresponsive to tablets [letter]. Ann Intern Med. 1997;126:332–333
  23. Pons V, Greenspan D, Lozada-Nur F, McPhail L, Gallant JE, Tunkel A, et al.  Oropharyngeal candidiasis in patients with AIDS (Randomized comparison of fluconazole versus nystatin oral suspension). Clin Infect Dis. 1997;24:1204–1207

PII: S1368-8375(01)00063-X

Oral Oncology
Volume 38, Issue 4 , Pages 337-342 , June 2002

Article Tools